Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

October 2020 — Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.

Our role in the transaction

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.

Service

Funding, debt advisory & ECM

Parties

“It was particularly pleasing to see the level of support received for this financing, reinforcing confidence in SNG001, our wholly-owned drug and potential breakthrough treatment for COVID-19 patients. Oaklins’ team has always been supportive and built a good register of institutions in March which was broadened further in this funding. It was a very successful fundraising and the level of demand was such that we were comfortably able to increase the size of the funding. Having demonstrated the great promise of SNG001 in hospitalized COVID-19 patients earlier this year, we now have the resources to be able to rapidly progress this potential breakthrough treatment in such a critical area of unmet need.”

Richard Marsden

CEO, Synairgen plc

Talk to the deal team

Geoff Nash

Director

London, United Kingdom
Oaklins Cavendish

View profile Get in touch

Related deals

Tandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi

Food & Beverage

Tandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi

Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.

Learn more

ICOP has transferred its listing from Euronext Growth Milan to Euronext Milan

Construction & Engineering Services

ICOP has transferred its listing from Euronext Growth Milan to Euronext Milan

ICOP S.p.A. has transferred its listing from Euronext Growth Milan to Euronext Milan.

Learn more

Röntgeninstitut Aarau has been acquired by Evidia

Healthcare

Röntgeninstitut Aarau has been acquired by Evidia

The owners of Röntgeninstitut Aarau have sold the business to Evidia Group as part of their succession planning. The former owners will remain involved in the institute and support its future development alongside Evidia.

Learn more